Wesley Yip1, Akbar Ashrafi1, Siamak Daneshmand2. 1. USC Institute of Urology/Norris Comprehensive Cancer Center, 1441 Eastlake Ave, Los Angeles, CA, 90033, USA. 2. USC Institute of Urology/Norris Comprehensive Cancer Center, 1441 Eastlake Ave, Los Angeles, CA, 90033, USA. daneshma@med.usc.edu.
Abstract
PURPOSE OF REVIEW: Bladder cancer is a deadly and common malignancy, with 24% of new cases presenting as T1 disease. High-grade T1 in particular represents a difficult entity to treat due to its clinical variability and known risks of recurrence, progression, and cancer-specific mortality. The differences in guidelines from major urologic organizations underscore this variability, and the past year has seen another BCG shortage, further complicating management. Advances have been made in the molecular and genomic characterization of high-grade T1, and new clinical trials are available to investigate alternative therapies. In this review, we summarize the variations in guidelines, alternatives to BCG, emerging molecular and genomic discoveries, and recent clinical trials. RECENT FINDINGS: Adherence to guidelines for non-muscle-invasive bladder cancer in the community among practicing urologists remains low, in part due to the variations in available guidelines. In the era of a BCG shortage, decreased dosing schedules and alternative intravesical options are increasingly being used. New biomarkers are being discovered to better risk-stratify patients, with future therapies aimed at targeting aggressive disease. HGT1 urothelial carcinoma remains a highly variable and aggressive disease, but we are making significant progress in better characterizing the clinical and molecular factors that influence recurrence and progression, to better guide management.
PURPOSE OF REVIEW: Bladder cancer is a deadly and common malignancy, with 24% of new cases presenting as T1 disease. High-grade T1 in particular represents a difficult entity to treat due to its clinical variability and known risks of recurrence, progression, and cancer-specific mortality. The differences in guidelines from major urologic organizations underscore this variability, and the past year has seen another BCG shortage, further complicating management. Advances have been made in the molecular and genomic characterization of high-grade T1, and new clinical trials are available to investigate alternative therapies. In this review, we summarize the variations in guidelines, alternatives to BCG, emerging molecular and genomic discoveries, and recent clinical trials. RECENT FINDINGS: Adherence to guidelines for non-muscle-invasive bladder cancer in the community among practicing urologists remains low, in part due to the variations in available guidelines. In the era of a BCG shortage, decreased dosing schedules and alternative intravesical options are increasingly being used. New biomarkers are being discovered to better risk-stratify patients, with future therapies aimed at targeting aggressive disease. HGT1urothelial carcinoma remains a highly variable and aggressive disease, but we are making significant progress in better characterizing the clinical and molecular factors that influence recurrence and progression, to better guide management.
Authors: Paolo Gontero; Richard Sylvester; Francesca Pisano; Steven Joniau; Kathy Vander Eeckt; Vincenzo Serretta; Stéphane Larré; Savino Di Stasi; Bas Van Rhijn; Alfred J Witjes; Anne J Grotenhuis; Lambertus A Kiemeney; Renzo Colombo; Alberto Briganti; Marek Babjuk; Per-Uno Malmström; Marco Oderda; Jacques Irani; Nuria Malats; Jack Baniel; Roy Mano; Tommaso Cai; Eugene K Cha; Peter Ardelt; John Varkarakis; Riccardo Bartoletti; Martin Spahn; Robert Johansson; Bruno Frea; Viktor Soukup; Evanguelos Xylinas; Guido Dalbagni; R Jeffrey Karnes; Shahrokh F Shariat; Joan Palou Journal: Eur Urol Date: 2014-07-16 Impact factor: 20.096
Authors: Roger Chou; Shelley Selph; David I Buckley; Rongwei Fu; Jessica C Griffin; Sara Grusing; John L Gore Journal: J Urol Date: 2016-12-24 Impact factor: 7.450
Authors: Per-Uno Malmström; Richard J Sylvester; David E Crawford; Martin Friedrich; Susanne Krege; Erkki Rintala; Eduardo Solsona; Savino M Di Stasi; J Alfred Witjes Journal: Eur Urol Date: 2009-04-24 Impact factor: 20.096
Authors: Elisabeth E Fransen van de Putte; Judith Bosschieter; Theo H van der Kwast; Simone Bertz; Stefan Denzinger; Quentin Manach; Eva M Compérat; Joost L Boormans; Michael A S Jewett; Robert Stoehr; Geert J L H van Leenders; Jakko A Nieuwenhuijzen; Alexandre R Zlotta; Kees Hendricksen; Morgan Rouprêt; Wolfgang Otto; Maximilian Burger; Arndt Hartmann; Bas W G van Rhijn Journal: BJU Int Date: 2018-04-27 Impact factor: 5.588
Authors: Sam S Chang; Stephen A Boorjian; Roger Chou; Peter E Clark; Siamak Daneshmand; Badrinath R Konety; Raj Pruthi; Diane Z Quale; Chad R Ritch; John D Seigne; Eila Curlee Skinner; Norm D Smith; James M McKiernan Journal: J Urol Date: 2016-06-16 Impact factor: 7.450